Literature DB >> 19825364

The TRIF-dependent signaling pathway is not required for acute cerebral ischemia/reperfusion injury in mice.

Fang Hua1, Jun Wang, Iqbal Sayeed, Tauheed Ishrat, Fahim Atif, Donald G Stein.   

Abstract

TIR domain-containing adaptor protein (TRIF) is an adaptor protein in Toll-like receptor (TLR) signaling pathways. Activation of TRIF leads to the activation of interferon regulatory factor 3 (IRF3) and nuclear factor kappa B (NF-kappaB). While studies have shown that TLRs are implicated in cerebral ischemia/reperfusion (I/R) injury and in neuroprotection against ischemia afforded by preconditioning, little is known about TRIF's role in the pathological process following cerebral I/R. The present study investigated the role that TRIF may play in acute cerebral I/R injury. In a mouse model of cerebral I/R induced by transient middle cerebral artery occlusion, we examined the activation of NF-kappaB and IRF3 signaling in ischemic cerebral tissue using ELISA and Western blots. Neurological function and cerebral infarct size were also evaluated 24h after cerebral I/R. NF-kappaB activity and phosphorylation of the inhibitor of kappa B (IkappaBalpha) increased in ischemic brains, but IRF3, inhibitor of kappaB kinase complex-epsilon (IKKepsilon), and TANK-binding kinase1 (TBK1) were not activated after cerebral I/R in wild-type (WT) mice. Interestingly, TRIF deficit did not inhibit NF-kappaB activity or p-IkappaBalpha induced by cerebral I/R. Moreover, although cerebral I/R induced neurological and functional impairments and brain infarction in WT mice, the deficits were not improved and brain infarct size was not reduced in TRIF knockout mice compared to WT mice. Our results demonstrate that the TRIF-dependent signaling pathway is not required for the activation of NF-kappaB signaling and brain injury after acute cerebral I/R.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19825364      PMCID: PMC2787898          DOI: 10.1016/j.bbrc.2009.10.027

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  Toll-like receptors: critical proteins linking innate and acquired immunity.

Authors:  S Akira; K Takeda; T Kaisho
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

2.  Three novel mammalian toll-like receptors: gene structure, expression, and evolution.

Authors:  X Du; A Poltorak; Y Wei; B Beutler
Journal:  Eur Cytokine Netw       Date:  2000-09       Impact factor: 2.737

Review 3.  Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia.

Authors:  G Stoll
Journal:  Rev Neurol (Paris)       Date:  2002-10       Impact factor: 2.607

4.  Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes.

Authors:  T Kawai; O Takeuchi; T Fujita; J Inoue; P F Mühlradt; S Sato; K Hoshino; S Akira
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

5.  Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells.

Authors:  T Chuang; R J Ulevitch
Journal:  Biochim Biophys Acta       Date:  2001-03-19

Review 6.  Toll signaling pathways in the innate immune response.

Authors:  K V Anderson
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

Review 7.  The inflammatory response in cerebral ischemia: focus on cytokines in stroke patients.

Authors:  Maria Grazia De Simoni; Paolo Milia; Michela Barba; Ada De Luigi; Lucilla Parnetti; Virgilio Gallai
Journal:  Clin Exp Hypertens       Date:  2002 Oct-Nov       Impact factor: 1.749

8.  TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages.

Authors:  Vladimir Toshchakov; Bryan W Jones; Pin-Yu Perera; Karen Thomas; M Joshua Cody; Shuling Zhang; Bryan R G Williams; Jennifer Major; Thomas A Hamilton; Matthew J Fenton; Stefanie N Vogel
Journal:  Nat Immunol       Date:  2002-03-18       Impact factor: 25.606

9.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

10.  Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation.

Authors:  Katsuaki Hoshino; Tsuneyasu Kaisho; Tomio Iwabe; Osamu Takeuchi; Shizuo Akira
Journal:  Int Immunol       Date:  2002-10       Impact factor: 4.823

View more
  17 in total

1.  TLR2 ligand induces protection against cerebral ischemia/reperfusion injury via activation of phosphoinositide 3-kinase/Akt signaling.

Authors:  Chen Lu; Li Liu; Yuling Chen; Tuanzhu Ha; Jim Kelley; John Schweitzer; John H Kalbfleisch; Race L Kao; David L Williams; Chuanfu Li
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

2.  Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases.

Authors:  Tauheed Ishrat; Iqbal Sayeed; Fahim Atif; Fang Hua; Donald G Stein
Journal:  Exp Neurol       Date:  2010-09-15       Impact factor: 5.330

3.  TLR-4-dependent and -independent mechanisms of fetal brain injury in the setting of preterm birth.

Authors:  Kelsey Breen; Amy Brown; Irina Burd; Jinghua Chai; Alexander Friedman; Michal A Elovitz
Journal:  Reprod Sci       Date:  2012-08       Impact factor: 3.060

Review 4.  The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.

Authors:  Bolanle M Famakin
Journal:  Aging Dis       Date:  2014-10-01       Impact factor: 6.745

5.  Disruption of downstream MyD88 or TRIF Toll-like receptor signaling does not protect against cerebral ischemia.

Authors:  Bolanle M Famakin; Yongshan Mou; Christl A Ruetzler; Joliet Bembry; Dragan Maric; John M Hallenbeck
Journal:  Brain Res       Date:  2011-03-01       Impact factor: 3.252

6.  Recombinant high-mobility group box 1 protein (HMGB-1) promotes myeloid differentiation primary response protein 88 (Myd88) upregulation in mouse primary cortical neurons.

Authors:  Wei Li; Hai-Ping Ling; Wan-Chun You; Xiang-Jun Ji; Yong Tang; Jin-Bing Zhao; Xing-Fen Su; Chun-Hua Hang
Journal:  Neurol Sci       Date:  2012-06-19       Impact factor: 3.307

7.  TLR2 modulates antibodies required for intestinal ischemia/reperfusion-induced damage and inflammation.

Authors:  Michael R Pope; Sherry D Fleming
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

8.  Involvement of the TLR4 (Toll-like receptor4) signaling pathway in palmitate-induced INS-1 beta cell death.

Authors:  Sung-Mi Lee; Sung-E Choi; Ji-Hyun Lee; Jung-Jin Lee; Ik-Rak Jung; Soo-Jin Lee; Kwan-Woo Lee; Yup Kang
Journal:  Mol Cell Biochem       Date:  2011-04-19       Impact factor: 3.396

9.  Toll-like receptor-3 activation increases the vulnerability of the neonatal brain to hypoxia-ischemia.

Authors:  Linnea Stridh; Amin Mottahedin; Maria E Johansson; Raul Chavez Valdez; Frances Northington; Xiaoyang Wang; Carina Mallard
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

Review 10.  A Molecular Approach to Epilepsy Management: from Current Therapeutic Methods to Preconditioning Efforts.

Authors:  Elham Amini; Mohsen Rezaei; Norlinah Mohamed Ibrahim; Mojtaba Golpich; Rasoul Ghasemi; Zahurin Mohamed; Azman Ali Raymond; Leila Dargahi; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.